Table 2.
Outcome.
| RR (Overall) | n = 41 (%) | |
|---|---|---|
| PR | 5 (12) | |
| SD | 7 (17) | |
| DCR | 12 (29) | |
| RR (II line) | n = 33 (%) | |
| PR | 4 (12) | |
| SD | 7 (21) | |
| DCR | 11 (33) | |
| RR (III and IV line) | n = 8 (%) | |
| PR | 1 (13) | |
| SD | 0 (0) | |
| DCR | 1 (13) | |
| PFS (months) | ||
| mPFS | n = 38 | |
| 2.2 | ||
| mPFS (DCR pts) | n = 12 | |
| 7.2 | ||
| OS (months) | ||
| mOS (Overall) | n = 43 | |
| 6.9 | ||
| mOS (VIN II line) | n = 35 | |
| 11.8 | ||
| mOS (VIN III–IV line) | n = 8 | |
| 5.6 |
RR, Response Rate; PR, Partial Response; SD, Stable Disease; DCR, Disease Control (PR+SD); PFS, Progression Free Survival; mPFS, median PFS; OS, Overall Survival; mOS, median OS; VIN, Vinflunine.